This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2010 by Medical University of Vienna.
Recruitment status was:  Recruiting
Information provided by:
Medical University of Vienna Identifier:
First received: November 20, 2008
Last updated: August 17, 2010
Last verified: August 2010
Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes induced by docetaxel in HRPC patients

Condition Intervention Phase
Hormone Refractory Prostate Cancer Drug: Docetaxel * Sunitinib Drug: Docetaxel Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Randomized, Controlled Biomarker Study Evaluating the Anti-angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Primary: CEC/CEP spikes induced by MTD docetaxel in patients treated with docetaxel/sunitinib relative to docetaxel monotherapy [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Response rate and length of treatment holidays relative to docetaxel monotherapy [ Time Frame: 6 months ]

Estimated Enrollment: 60
Study Start Date: November 2008
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Docetaxel + Sunitinib
docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
Drug: Docetaxel * Sunitinib
docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
Other Name: Taxotere + Sutent
Active Comparator: Taxotere
docetaxel 75mg/m2 day1 q 21d x 4 cycles
Drug: Docetaxel
docetaxel 75mg/m2 day1 q 21d x 4 cycles
Other Name: Taxotere
Drug: Docetaxel
Docetaxel 75mg/m2 q21d for 4 cycles
Other Name: Taxotere

Detailed Description:

Docetaxel (75mg/m2 q21d) is standard of care for patients with hormone refractory prostate cancer (HRPC). Recent data indicate, that chemotherapeutics given at MTD induce, besides their cytotoxic effects, mobilization of circulating endothelial cells (CEC) and - progenitors (CEP) in drug-free breaks of each cycle. In preclinical models, mobilized CEC/CEP result in tumor vasculogenesis and progression of disease.

We hypothesize that treatment with sunitinib, an anti-angiogenic tyrosine kinase inhibitor, in between 3 weekly docetaxel disrupts CEC/CEP spikes following docetaxel leading to chemosensitization and reduced tumor re-growth in HRPC patients responding to docetaxel.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • WHO performance status of 0-2.
  • Histologically proven prostate adenocarcinoma.
  • All patients must have prostate adenocarcinoma that is unresponsive or refractory to androgen ablation with biochemical progression
  • Measurable and/or evaluable progressive disease, which is defined by one of the following three criteria:

    • 25% increase in bidimensionally measurable soft tissue metastases
    • Appearance of new metastatic lesions (proven by CT scan, X-ray or bone scan)
    • PSA level of at least 10ng/mL, with increases on at least 2 successive occasions at least 2 weeks apart
  • If the patient has been treated with antiandrogens, treatment must have been stopped at least 6 weeks prior to study randomization

Exclusion Criteria:

- prior chemotherapy for prostate cancer

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00795171

Contact: Michael MK Krainer, MD +43 1 40400 ext 4445

Dept of Internal Medicine Recruiting
Vienna, Austria, 1090
Contact: Volker VW Wacheck, MD    +43 1 40400 ext 2989   
Principal Investigator: Michael , MK Krainer, MD         
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Michael MK Krainer, MD Dept of Internal Medicine I, Medical University Vienna, Austria
  More Information

Responsible Party: Dept of Internal Medicine I, Medical University Vienna, Austria, Medical University Vienna, Austria Identifier: NCT00795171     History of Changes
Other Study ID Numbers: MK URO 4
EUDRACT 2007-003705-27
Study First Received: November 20, 2008
Last Updated: August 17, 2010

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on August 16, 2017